INTRODUCTION {#sec1-1}
============

Alopecia areata (AA) is an autoimmune disease with a lifetime prevalence of 2%.\[[@ref1]\] Loss of immune privilege leads to arrest of hairs in the anagen phase resulting in nonscarring hair loss. AA is characterized by small patches of hair loss within normal hair-bearing skin. The variants of AA include alopecia totalis (AT), characterized by complete loss of scalp hair; alopecia universalis (AU), characterized by complete loss of scalp and other body hair; and ophiasis pattern AA, characterized by hair loss localized to the temporal and occipital scalp. Loss of hair is considered as an autoimmune process leading to chronic inflammation due to the presence of organ-specific CD8+ T-cell-dependent response mainly affecting hair follicles.\[[@ref2]\] Various triggers such as infections, trauma, hormones, and stress are known to worsen the disease.\[[@ref3]\] Genetic component plays an important role with likelihood of severe symptoms seen in first-degree relative.\[[@ref4]\] Association with other autoimmune diseases such as vitiligo, lupus erythematosus, psoriasis, atopic dermatitis, thyroid disease, allergic rhinitis, pernicious anemia, diabetes mellitus, and rheumatoid arthritis is known.\[[@ref5]\] Topical/intralesional steroids and various immunosuppressants had been tried with varying rate of success. AT and universalis are often resistant to such therapies and are prone to frequent relapses.

AA occurs as a result of breech in the immune privilege of anagen hair follicles. It is mediated by the suppression of major histocompatibility complex (MHC) Class I and shutdown of pro-inflammatory mechanisms including action of antigen-presenting cells (APCs), mast cells, and natural killer cells. Disruption in these mechanisms leads to collapse of immune privilege leading to onset and progression of AA. The immune mechanism is mediated by CD8+ NKG2D+ T-cells through interleukin (IL)-15-positive feedback loop within follicular epithelial cells, mediated through Janus kinase (JAK) signaling pathway.\[[@ref6]\] There is an accumulation of CD8+/CD4+ lymphocytes and APC around hair follicles, and increase in the substance *P* mediates transition from anagen phase to catagen phase resulting in characteristic nonscarring hair loss. Hair loss is induced due to arrest of growth phase leading to premature senescence rather than direct immune-mediated follicular destruction.\[[@ref7]\] Selective involvement of black hairs suggests that the autoantigen displayed by MHC I is both anagen and melanogenesis associated. The treatment of AA is challenging, and there is no Food and Drug Administration (FDA)-approved therapy.\[[@ref8]\] While a variety of therapies are commonly used, none of them are reliably effective, especially for the treatment of severe AA, AT, and AU.\[[@ref8]\] An important therapeutic insight was the discovery that blockade of common signaling pathways downstream of cytokine receptors, in particular JAK/STAT, could reverse AA in mice.\[[@ref9]\]

METHODS {#sec1-2}
=======

Six patients diagnosed with AU/AT refractory to immunosuppressants and with rapidly progressing disease were selected. Detailed history regarding the disease process, previous treatments, and associated comorbidities was recorded. Complete hemogram, liver function test, renal parameters, ultrasound abdomen, chest X-ray, and Mantoux test were done. Herpes zoster vaccination was given for all the patients before starting the therapy. Severity of AA was assessed using the Severity of Alopecia Tool (SALT) score. A patient was initially started on oral tofacitinib 5 mg BID for 4 weeks later, and the dose was increased up to 10 mg BID. Treatment response was assessed based on physical assessment, photographic evaluation, dermoscopic changes, and SALT score analysis. Adverse reactions were monitored by blood investigations done at 2 monthly interval. All the patients will be followed up for at least 6 months after stopping the therapy to assess any relapse.

RESULTS {#sec1-3}
=======

All our patients (5 patients with AU, 1 patient with AT) showed dramatic response to oral tofacitinib. The mean treatment duration was 3--6 months. Patient characteristics with treatment protocol are listed in [Table 1](#T1){ref-type="table"}. Baseline and subsequent SALT score analysis and median change are mentioned in [Table 2](#T2){ref-type="table"}. All the patients were initially reviewed after 4 weeks, and the dose was increased to 10 mg BID. By 8 weeks, there was a formation of vellus hair follicles \[[Figure 1](#F1){ref-type="fig"}\]. Therapy was continued till complete regrowth of hairs. Among our patients, initial regrowth was first seen over the eyebrows and beard followed by the scalp. Our patients are currently in follow-up and one among them is under remission after stopping the drug for 4 months. One patient relapsed with loss of hair over eyebrows within 2 months of stopping the drug. Clinical representative photographs of response to the drug are presented in [Figure 2](#F2){ref-type="fig"}. No serious adverse side effects were encountered. Two of our patients developed acneiform eruptions which were managed with topicals.
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![(a) Pre- and posttreatment improvement in regrowth of eyebrows (kajal applied by the patient in pretreatment picture at 4 months. (b) Pre- and posttreatment regrowth of scalp hairs by 4 months. (c) Dermoscopy picture showing vellus hairs at 8 weeks and 12 weeks showing terminal hairs](IJT-10-103-g003){#F1}

![(a) Photographs taken at baseline. (b) At 12 weeks of therapy. (c) At 4 months after starting tofacitinib](IJT-10-103-g004){#F2}

DISCUSSION {#sec1-4}
==========

JAK inhibitors (jakinibs) are groups of drugs that inhibit the JAK family of enzymes interfering with the JAK-STAT signaling pathway. Tofacitinib is a selective targeted kinase inhibitor that it mainly inhibits JAK3, thus blocking the upregulation of interferon (IFN)-gamma in CD8+ lymphocytes.\[[@ref9]\] Therapeutically, antibody-mediated blockade of IFN-γ, IL-2, or IL-15 receptor β prevented disease development, reducing the accumulation of CD8 (+) NKG2D (+) T-cells in the skin and the dermal IFN response in a mouse model of AA.\[[@ref9]\] Systemically administered pharmacological inhibitors of JAK family protein tyrosine kinases, downstream effectors of the IFN-γ and γc cytokine receptors, eliminated the IFN signature and prevented the development of AA. There is an interruption of the feedback loop, and the hair follicles are able to return to anagen. Tofacitinib was initially FDA approved for the treatment of rheumatoid arthritis.\[[@ref10]\] It was after a milestone paper published by Craiglow and King showing that the Renbok phenomenon of hair growth in AA patches in a psoriasis patient treated with tofacitinib provoked further research and use of this drug in AA.\[[@ref11]\] It also currently has been investigated for its benefits in psoriasis, inflammatory bowel disease, and prevention of transplant rejection. Side effects of jakinibs are anemia, thrombocytopenia, and neutropenia due to JAK2 inhibition. Deranged lipid profile was seen in RA patients taking tofacitinib. Other serious adverse effects are bacterial and fungal infections. There are reports of reactivation of TB and herpes zoster in patients during Phase 3 trials. Further studies are required to establish the drug safety profile and long-term side effects.

Other studies point to a role for JAK inhibition in treating AA. In an uncontrolled retrospective study by Liu *et al*. of 90 adults with AT, AU, or moderate-to-severe AA, 58% had SALT scores of 50% or better after receiving 5 mg tofacitinib twice daily for 4--18 months. Patients with AA improved more than those with AT or universalis. There were no severe adverse effects although nearly a third of patients developed upper respiratory tract infections.\[[@ref12]\] In another uncontrolled study by Craiglow *et al*. of 13 patients with AA, totalis, or universalis, 9 (70%) patients achieved full regrowth and there were no serious adverse effects although patients experienced headaches, upper respiratory infections, and mild increases in liver transaminase levels.\[[@ref13]\]

Other jakinibs such as ruxolitinib and baricitinib \[[@ref14]\] are being used for AA. In this pilot study by Mackay-wiggan *et al*., 9 of 12 patients (75%) treated with ruxolitinib showed significant scalp hair regrowth and improvement of AA with ruxolitinib.\[[@ref15]\]

Recently, topical formulation of tofacitinib and ruxolitinib is available and is shown to have positive results. About 0.6% ruxolitinib cream used twice daily for 12 weeks in a case of refractory AU resulted in full eyebrow regrowth and also 10% of scalp hair regrowth.\[[@ref16]\]

CONCLUSION {#sec1-5}
==========

The immune pathways required for autoreactive T-cell activation in AA are not defined limiting clinical development of rational targeted therapies. There are only few studies in the literature showing the efficacy of tofacitinib and ruxolitinib in the treatment of AU.\[[@ref12][@ref16][@ref17][@ref18]\] There are no severe adverse reactions reported for the drug; till now, two of our patients had developed acneiform reactions. One of the shortcoming of the drug is a progression of disease/recurrence after stopping the drug as reported by few studies suggesting maintenance therapy for remission.\[[@ref12][@ref15]\] This is the first published case series of successful treatment with tofacitinib from India although the sample size was small. All our patients started with the drug responded dramatically with satisfactory regrowth of hair and arrest in disease progression. Currently, the patients are in follow-up period. Relapse of the disease following discontinuation of the drug has been reported by few studies as happened in one of our patients. Further larger clinical trials are needed to establish the safety profile, long-term side effects, and disease remission protocol.
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